Nektar Therapeutics (NKTR) Reports Q4 Loss of $0.21

Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.21), versus ($0.28) reported last year. Revenue for the quarter came in at $95.5 million, versus $37.5 million reported last year.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c